Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2070]

Genomic sequencing to find AML-causing mutations

Dr George Vassiliou - Cambridge Cancer Centre, Cambridge, UK

Genomic sequencing to find AML-causing mutations ( Dr George Vassiliou - Cambridge Cancer Centre, Cambridge, UK )

Measuring molecular responses to tyrosine kinase inhibitors in chronic myeloid...

Prof Susan Branford - Adelaide University Adelaide, Australia

Measuring molecular responses to tyrosine kinase inhibitors in chronic myeloid leukaemia ( Prof Susan Branford - Adelaide University Adelaide, Australia )

New definition for multiple myeloma improves patient outcomes

Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA

New definition for multiple myeloma improves patient outcomes ( Prof Vincent Rajkumar - Mayo Clinic, Rochester, USA )

Factors influencing response to blinatumomab in relapsed/refractory ALL

Prof Max Topp - Würzburg University Hospital, Würzburg, Germany

$Factors influencing response to blinatumomab in relapsed/refractory ALL ( Prof Max Topp - Würzburg University Hospital, Würzburg, Germany )$

DNMT3A R882 mutations promote chemoresistance and residual disease in AML

Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA

DNMT3A R882 mutations promote chemoresistance and residual disease in AML ( Dr Olga Guryanova - Memorial Sloan Kettering Cancer Center, New York, USA )

First randomised evidence for kinase inhibitor activity in acute myeloid...

Dr Gerhard Ehninger - University Hospital Dresden, Dresden, Germany

First randomised evidence for kinase inhibitor activity in acute myeloid leukaemia ( Dr Gerhard Ehninger - University Hospital Dresden, Dresden, Germany )

Preliminary analysis on the RNA sequencing data of lung squamous cell carcinoma

Prof Yilong Wu - President of the Chinese Society of Clinical Oncology

Preliminary analysis on the RNA sequencing data of lung squamous cell carcinoma ( Prof Yilong Wu - President of the Chinese Society of Clinical Oncology )

Survival benefits following eribulin in advanced liposarcoma and leiomyosarcoma

Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium

Survival benefits following eribulin in advanced liposarcoma and leiomyosarcoma ( Dr Patrick Schöffski - University Hospitals Leuven, Leuven, Belgium )

ASCO 2015: Latest developments in multiple myeloma

Prof Philippe Moreau, Prof Sagar Lonial, Prof Meletios Dimopoulos

ASCO 2015: Latest developments in multiple myeloma ( Prof Philippe Moreau, Prof Sagar Lonial, Prof Meletios Dimopoulos )

ASCO 2015: Latest in chronic lymphocytic leukaemia

Prof Stephan Stilgenbauer and Dr Jacqueline Barrientos

ASCO 2015: Latest in chronic lymphocytic leukaemia ( Prof Stephan Stilgenbauer and Dr Jacqueline Barrientos )

Subgroup analysis of molecular markers in phase III study of high risk low...

Dr Brigitta Baumert - Robert Janker Klinic, Bonn, Germany

Subgroup analysis of molecular markers in phase III study of high risk low-grade glioma ( Dr Brigitta Baumert - Robert Janker Klinic, Bonn, Germany )

Advanced DNA sequencing test used to match rare cancers

Dr James Doroshow, Dr Keith Flaherty and Dr Barbara Conley

Advanced DNA sequencing test used to match rare cancers ( Dr James Doroshow, Dr Keith Flaherty and Dr Barbara Conley )

More from ecancer